COVID-19 treatment ranges from simple rest and over-the-counter symptom relief for mild cases to antiviral drugs, corticosteroids, and intensive care support for moderate and severe illness. The right approach depends almost entirely on how sick you are, how quickly the illness is progressing, and whether you have risk factors that make complications more likely. What started as a disease with no targeted treatments in early 2020 now has a layered toolkit, though the landscape keeps shifting as the virus evolves and the population’s immunity changes.
How Doctors Classify Severity
The treatment you receive hinges on which severity category you fall into, and different health systems have drawn those lines somewhat differently. In general, the categories work like this: mild illness means you have symptoms like fever, cough, or body aches but no shortness of breath and normal oxygen levels. Moderate illness involves evidence of lower respiratory disease, such as abnormal imaging or oxygen saturation dipping during activity, but you can still maintain adequate oxygen on your own. Severe illness means you need supplemental oxygen, and critical illness means you need mechanical ventilation or have organ failure.
In South Korea, classification during the pandemic relied on vital signs including pulse, blood pressure, respiratory rate, temperature, and level of consciousness, which allowed health-care staff to sort patients into severity tiers at the point of care.1PubMed Central. Disease severity classification and COVID-19 outcomes, Republic of Korea Other approaches have used respiratory support requirements at hospital admission, categorizing patients by whether they needed no oxygen, supplemental oxygen or non-invasive ventilation, or invasive mechanical ventilation.2PubMed Central. Categorization of COVID‐19 severity to determine mortality risk Chinese guidelines distinguished mild cases (minimal symptoms with clear lung imaging) from common and severe-critical groups based on CT findings and clinical severity.3PubMed Central. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) The details vary, but the core idea is universal: treatment escalates in lockstep with how much respiratory support your body needs.
Antiviral Treatment for Mild Cases
Most people who catch COVID-19 develop mild symptoms and recover at home without hospitalization.4PubMed Central. Use of home remedies for the treatment and prevention of coronavirus disease: an integrative review For those people, basic supportive care is the foundation: staying hydrated, resting, using acetaminophen or ibuprofen for fever and aches, and monitoring symptoms for any signs of worsening. Most mild cases resolve on their own within a week or two.
The question is when to add antiviral drugs on top of that baseline. The clearest benefit goes to people at higher risk of progressing to severe disease, which includes older adults, people with chronic conditions like diabetes or heart disease, and those who are immunocompromised. For these groups, starting antiviral treatment early can make a meaningful difference.
Nirmatrelvir-ritonavir (Paxlovid) is the most widely prescribed oral antiviral. It works by blocking a protease the virus needs to replicate. In its original trial, it showed a greater reduction in hospitalization and death than molnupiravir, the other main oral antiviral, and both drugs need to be started within five days of symptom onset and taken for five days.5Clinical Infectious Diseases. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs Real-world data from China during the Omicron wave confirmed that Paxlovid recipients had substantially lower 28-day mortality compared to matched controls who received no antiviral.6PubMed. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study
However, the picture shifted as population immunity grew through vaccination and prior infection. A large trial in standard-risk adults (both vaccinated and unvaccinated) found that nirmatrelvir-ritonavir shortened symptom recovery by only about one day compared to placebo, and the reduction in hospitalization or death was small and not statistically definitive.7New England Journal of Medicine. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 This suggests that the drug’s benefit is concentrated in people who genuinely face elevated risk, not in the average healthy adult who catches a mild case.
Remdesivir, an intravenous antiviral, has also been studied for outpatient use in high-risk patients. A trial found that a three-day outpatient course reduced hospitalization or death by about 87% compared to placebo in unvaccinated, high-risk adults with early symptoms.8PubMed. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients A subsequent study focusing on immunosuppressed patients during the Omicron era found a similar magnitude of benefit.9PubMed Central. Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study The catch is that remdesivir requires intravenous infusion, which makes it less practical than pills. It tends to be reserved for situations where oral antivirals are contraindicated or unavailable.
Hospital Treatment for Moderate COVID-19
If your oxygen levels drop or your breathing worsens enough to require hospitalization, the treatment toolkit expands. Two drugs form the backbone of moderate COVID-19 care in the hospital: remdesivir and dexamethasone.
Remdesivir, given intravenously for up to five days in hospitalized patients, shortened the median recovery time from 15 days to 10 days in a major randomized trial, and patients receiving it were more likely to show clinical improvement by day 15.10PubMed. Remdesivir for the Treatment of Covid-19 – Final Report Timing matters: patients who started remdesivir within three days of their positive test had shorter hospital stays and lower odds of needing mechanical ventilation than those who started later.11PubMed Central. Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes A Retrospective Observational Study
Dexamethasone, a cheap and widely available corticosteroid, was one of the first treatments shown to reduce deaths. The landmark RECOVERY trial found that it cut mortality among patients on invasive mechanical ventilation by roughly a third and reduced deaths among those receiving supplemental oxygen without ventilation as well.12PubMed. Dexamethasone in Hospitalized Patients with Covid-19 A critical detail: among patients who were not receiving any respiratory support at the time of enrollment, dexamethasone did not help and may have caused slight harm. The drug works by dampening the overactive immune response that drives lung damage in severe disease, so using it too early, before that inflammatory cascade has kicked in, can be counterproductive.
For patients who need high-flow oxygen or non-invasive ventilation, combining remdesivir with dexamethasone has shown additional benefit. In a cohort of severe patients on advanced respiratory support, combining the two drugs cut the 28-day intubation rate roughly in half compared to dexamethasone alone.13PubMed Central. Remdesivir plus Dexamethasone in COVID-19: A cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation
Intensive Care for Critical Cases
When COVID-19 progresses to critical illness, treatment shifts from trying to shorten the disease to trying to keep the patient alive while their body fights it. This means aggressive respiratory support and managing the runaway inflammatory response.
One surprisingly simple intervention has made a real difference: having patients lie face down, known as prone positioning. Even in awake patients who are not on a ventilator, this improves oxygen distribution in the lungs. Evidence supports using it in patients with acute low-oxygen respiratory failure who are on high-flow nasal cannula in an ICU setting.14PubMed Central. Awake prone positioning for patients with COVID-19-induced acute hypoxemic respiratory failure It costs nothing and carries very little risk, which made it especially valuable early in the pandemic when drug options were scarce.
When the immune system’s inflammatory response spirals out of control, drugs that block specific immune pathways can help. Baricitinib and tocilizumab are two immunomodulators used in hospitalized patients with rapidly worsening disease. A real-world study comparing the two found similar 28-day mortality rates, though patients who received tocilizumab were more likely to require invasive mechanical ventilation.15PubMed Central. Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study These drugs are typically added on top of corticosteroids and antivirals, not used instead of them.
For patients whose lungs fail despite maximum conventional support, extracorporeal membrane oxygenation (ECMO) is the last resort. The machine takes over the work of the lungs, pulling blood out of the body, oxygenating it, and returning it. The standard approach for COVID-19 respiratory failure has been veno-venous ECMO, though patients with severe heart dysfunction sometimes need configurations that support the heart as well.16PubMed Central. Extracorporeal membrane oxygenation for COVID-19-related acute respiratory distress syndrome: a narrative review A French cohort study documented that ECMO rapidly normalized blood gases and allowed doctors to reduce the mechanical force the ventilator was delivering to the lungs, buying them time to heal.17The Lancet Respiratory Medicine. Clinical characteristics and outcomes of patients with severe coronavirus disease 2019 requiring extracorporeal membrane oxygenation: a retrospective cohort study in France ECMO requires highly specialized teams and equipment, so it is only available at select medical centers.
Blood Clots and Secondary Infections
COVID-19 does not just attack the lungs. Hospitalized patients face an elevated risk of blood clots, which can form in the deep veins of the legs or travel to the lungs. Heparin, a blood-thinning medication, has been a standard part of COVID-19 hospital care since early in the pandemic. Beyond its anticoagulant effect, heparin may also have anti-inflammatory and even antiviral properties.18PubMed Central. The Role of Heparin in COVID-19: An Update after Two Years of Pandemics There has been debate about whether to use standard preventive doses or higher therapeutic doses; the answer depends on how sick the patient is and their individual clotting risk.19PubMed Central. Heparin as a therapy for COVID-19: current evidence and future possibilities
Bacterial co-infections are another complication, especially in patients on ventilators. In one study, about 12% of hospitalized COVID-19 patients developed secondary bacterial infections.20PubMed Central. Bacterial co-infections and antibiotic resistance in patients with COVID-19 These infections are treated with antibiotics, following standard guidelines for hospital-acquired and ventilator-associated pneumonia rather than any COVID-specific antibiotic protocol.21PubMed Central. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline Routine antibiotic use in COVID-19 patients without evidence of bacterial infection is not recommended, as it drives antibiotic resistance without providing benefit.
Treatments That Did Not Work
The pandemic generated enormous public interest in repurposed drugs, and two in particular captured headlines: ivermectin and hydroxychloroquine. Despite early enthusiasm and widespread off-label use, large well-designed trials have consistently failed to show benefit for either drug.
A large randomized trial published in the New England Journal of Medicine found that ivermectin did not reduce hospital admissions or prolonged emergency department visits among outpatients with early COVID-19. About 15% of patients in both the ivermectin and placebo groups met the primary outcome, a difference too small to be meaningful.22PubMed. Effect of Early Treatment with Ivermectin among Patients with Covid-19 A separate randomized trial in hospitalized patients with severe COVID-19 found no difference in hospital stay duration or rates of respiratory deterioration and death between groups receiving ivermectin, hydroxychloroquine, or standard care alone.23PubMed Central. Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial
A systematic review of phase III clinical trials reinforced these findings: ivermectin did not reduce disease severity, need for mechanical ventilation, ICU admission, or death. Hydroxychloroquine similarly showed no benefit, and some studies found it caused worse outcomes and serious side effects.24PubMed Central. Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials The early laboratory hints that these drugs might work against the virus did not translate into real-world benefit for patients. This is a useful reminder that cell-culture activity and clinical effectiveness are very different things.
The Paxlovid Drug Interaction Problem
One of the biggest practical headaches with nirmatrelvir-ritonavir (Paxlovid) has nothing to do with the virus. Ritonavir, the booster component that keeps nirmatrelvir active in the body long enough to work, is a powerful inhibitor of liver enzymes that metabolize many common medications. This means Paxlovid can dangerously alter the levels of drugs you may already be taking, from certain blood thinners and heart medications to immunosuppressants and some psychiatric drugs.
The options for managing these interactions are limited. Because COVID-19 moves fast and the treatment window is short (those crucial first five days), there is rarely time for careful dose adjustments or laboratory monitoring of the other drug. In practice, doctors are often left with two pragmatic strategies: temporarily pausing the interacting medication for the five-day Paxlovid course, or counseling patients about symptoms to watch for and managing any additional risk as it comes.25PubMed Central. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications For some medications, neither option is safe, which means Paxlovid simply cannot be used.26PubMed Central. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) This is one of the main reasons why alternative antivirals like molnupiravir and remdesivir remain important. If you take multiple prescription medications, make sure whoever prescribes Paxlovid reviews your full medication list before you fill the prescription.
Treatment During Pregnancy
Treating COVID-19 in pregnant patients comes with extra uncertainty, because most drug trials excluded pregnant women. Remdesivir has been the most studied antiviral in this group, but a systematic review found the evidence for its safety and effectiveness in pregnancy to be inconclusive, recommending careful monitoring of liver enzymes if it is used.27Heliyon. Efficacy and safety of remdesivir for pregnant patients with coronavirus disease 2019 (COVID-19): A systematic review
A meta-analysis pooling data from over 1,600 pregnant patients found that treatments including remdesivir and monoclonal antibodies reduced the need for cesarean section. However, they did not reduce the risk of preterm delivery, neonatal ICU admission, stillbirth, or progression to severe disease.28PubMed Central. Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis The honest picture is that we have less data for pregnant patients than for the general population, and treatment decisions tend to involve weighing the known risks of worsening COVID-19 against the uncertain drug-safety profile. This is a conversation to have with your obstetric and infectious-disease care team together.
Treating Immunocompromised Patients
People with weakened immune systems, whether from organ transplants, cancer treatment, or autoimmune conditions, face a double challenge. They are more likely to develop severe COVID-19, and the virus can persist in their bodies for much longer, sometimes weeks or months, because their immune systems cannot clear it efficiently.
This has led clinicians to experiment with combination antiviral strategies. Some treatment centers have combined remdesivir with nirmatrelvir-ritonavir for extended courses of up to 10 days, sometimes adding a monoclonal antibody on top, to try to suppress the virus more aggressively.29PubMed Central. Antiviral Combination Treatment for COVID-19 in Immunocompromised Patients: Towards Defining Its Place in Therapy When nirmatrelvir-ritonavir cannot be used because of drug interactions with immunosuppressive medications, which is common in transplant recipients, molnupiravir has been substituted. These approaches are still being refined, and no single protocol has emerged as the clear standard. The principle is that immunocompromised patients generally benefit from more aggressive treatment started as early as possible.
What Happened to Monoclonal Antibodies
Early in the pandemic, monoclonal antibodies designed to neutralize the SARS-CoV-2 spike protein were among the most effective treatments available. Products like bamlanivimab, casirivimab-imdevimab, and sotrovimab could prevent hospitalization in high-risk outpatients when given early. But their Achilles’ heel was always viral evolution.
As new variants emerged, the target the antibodies were designed to hit kept changing. The B.1.351 (Beta) and P.1 (Gamma) variants showed complete resistance to bamlanivimab, and the FDA eventually revoked its emergency authorization as a standalone treatment.30PubMed Central. Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm? Specific mutations in the virus, particularly at the E484K position, reduced or eliminated the activity of multiple antibody classes.31Nature Medicine. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies By the time Omicron-lineage variants dominated, virtually all authorized monoclonal antibodies had lost their effectiveness, and their clinical use was sharply curtailed.32PubMed Central. Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
This is why small-molecule antivirals like nirmatrelvir and remdesivir, which target parts of the virus’s internal machinery that mutate less readily, have become the backbone of outpatient treatment. Monoclonal antibodies may return if new products are developed to match current circulating strains, but their track record illustrates how quickly a virus can outrun a treatment designed to match a single molecular shape.
Inhaled Steroids for Early Illness
One intriguing question has been whether inhaled corticosteroids, the kind of steroid inhalers used for asthma, could help if taken early in COVID-19. The idea is appealing: deliver an anti-inflammatory drug directly to the airways where the virus is doing the most damage, without the systemic side effects of oral or IV steroids.
An early phase 2 trial found that inhaled budesonide, started within seven days of symptom onset, reduced the likelihood of needing urgent medical care and shortened recovery time by about a day compared to usual care.33PubMed Central. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial That generated excitement, but larger follow-up studies gave more mixed results. A trial of inhaled fluticasone furoate, a different inhaled steroid, found no evidence that it shortened time to recovery compared to placebo.34PubMed Central. Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
A meta-analysis of 11 randomized trials tried to reconcile these findings. It concluded that inhaled corticosteroid users had a modestly higher rate of symptom improvement by day 14, but there was no clear reduction in hospitalization, death, or the need for urgent care visits.35PubMed. Inhaled corticosteroid for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials The upshot is that inhaled steroids are not harmful and might help symptoms somewhat, but they are not a reliable substitute for antiviral drugs in people at risk for severe disease. If you already use an inhaled steroid for asthma or COPD, there is good reason to keep using it, but starting one specifically to treat COVID-19 is not strongly supported by current evidence.
Long COVID After the Acute Phase
Even after the acute infection resolves, a significant fraction of people experience lingering symptoms. A meta-analysis estimated the worldwide prevalence of long COVID at roughly 45%, with fatigue being the most common complaint (affecting about a quarter of those studied), followed by shortness of breath and impairment of daily activities.36PubMed Central. Multidisciplinary Management Strategies for Long COVID: A Narrative Review That estimate includes a wide range of severity, from people with mild persistent brain fog to those unable to work for months. People who were hospitalized and women appear to be at higher risk, though the specific risk varies by symptom type.
There is currently no single drug proven to treat long COVID. Management is multidisciplinary and symptom-driven: physical rehabilitation for exercise intolerance, cognitive therapy for brain fog, sleep hygiene interventions for insomnia, and sometimes medications for specific symptoms like persistent cough or nerve pain. Some researchers are investigating whether early antiviral treatment during the acute phase reduces the risk of developing long COVID, but definitive answers are still being gathered. For now, the best strategy is aggressive treatment of the initial infection when warranted, gradual return to activity during recovery, and seeking specialist care if symptoms persist beyond a few weeks.